https://www.live-feeds.com/feed/biontech-s-mrna-cancer-vaccine-fails-phase-3-test-significantly-denting-analysts-confidenceContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/biontech-s-mrna-cancer-vaccine-fails-phase-3-test-significantly-denting-analysts-confidencehttps://www.live-feeds.com/feed/biontech-s-mrna-cancer-vaccine-fails-phase-3-test-significantly-denting-analysts-confidence#u126841Sat, 17 Oct 2026 05:51:45 +0000BioNTech's mRNA cancer vaccine, BNT113, failed to improve progression-free survival in a phase 2/3 trial involving advanced HPV16-positive head and neck cancer. The trial will continue to assess overall survival. This setback raises questions about the clinical promise of therapeutic mRNA technology. BioNTech's stock fell after the announcement.Why it mattersThis failure is a significant setback for BioNTech, which had been working to apply mRNA technology to cancer treatments. The company's stock price has been affected by the news. The trial's outcome may impact the futur